Swiss cancer drugs firm ADC Therapeutics has set the terms for ... manufacturing process used to create cell therapies. Eisai has retreated from the optimistic view of sales growth for ...

Seagen said that the antibody in its ADC may be superior to trastuzumab ... move into earlier lines of therapy and low-HER2 cancers. Eisai has retreated from the optimistic view of sales growth ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

ADC driver amplifiers perform many important functions, including buffering, amplitude scaling, single-ended-to-differential and differential-to-single-ended conversion, common-mode offset adjustment, ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.